AiCuris Anti-infective Cures GmbH

AiCuris is a pharmaceutical company focused on discovery, research and development of novel, resistance-breaking antiviral and antibacterial agents for the treatment of severe and potentially life-threatening infectious diseases. Since November 2017, the first product from AiCuris is on the market. PREVYMIS™ (letermovir), designed to inhibit the viral terminase of the human cytomegalovirus (CMV), was licensed to MSD and achieved market approval in the US, Europe and Japan for the prophylaxis of CMV infections in recipients of bone marrow transplants.

Further clinical programs include Pritelivir, a helicase-primase inhibitor, developed to treat recurrent herpes simplex and AIC649, a novel biological immunomodulator targeting Hepatitis B cure and Covid-19.

 


AiCuris at a glance:

 

Field of Activity Anti-infectives incl. antivirals (HCMV, HSV, Hepatitis B virus, SARS-CoV-2, Adenovirus) and antibacterials (fighting AMR).Pandemic & Resistance Emergency Preparedness – PREP Program
Ownership Structure and Financing Private investors, led by the family office of the Dres. Strüngmann, former owners of Hexal.
Partners Merck & Co. (MSD): Licensee of Letermovir, Lysando, Max-Planck-Institute, ICIQ, Cyclenium and others.
AiCuris intends to move its projects to clinical PoC before licensing/partnering.
Active in-licensing strategy for pre-clinical and early clinical projects. Company incubator (AiCubator) for early projects initated in 2020.
Products / Services AiCuris‘ Clinical Programs:
Letermovir (licensed to MSD): HCMV, marketed (HSCT), Ph 3 (SOT)
Pritelivir, HSV resistant, Phase 2/3
AIC649, Hepatitis B Virus,Phase 1 & SARS-CoV-2 treatment
Several preclinical approaches in the field of AMR and antivirals
Unique Selling Point Clear focus on Anti-infectives. Highly innovative antibiotic and antiviral drugs acting via new modes of action and/or from novel chemical classes.
Membership in networks / associations EFPIA, BEAM Alliance, BIO Deutschland, BioRiver
Date of Incorporation/
Number of Employees
2006/70

 


Contact :

Dr. Holger Zimmermann, CEO
Address Friedrich-Ebert-Str. 475 / Building 302
42117 Wuppertal
Telephone/Telefax +49 202 317 63 -0/-1177
E-Mail info@aicuris.com
Web-Address www.aicuris.com
Social media LinkedIn Twitter